The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.59, demonstrating a -1.4% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.59, demonstrating a -1.4% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain ...

PRINCETON, N.J., September 10, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on ...

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company.